The Supreme Court indefinitely froze a 5th Circuit ruling that would have ended mail-order mifepristone access, as Alito and Thomas dissented and the Comstock Act emerged as a new front.
A divided Supreme Court on May 14 indefinitely extended a stay of a 5th U.S. Circuit Court of Appeals ruling that would have eliminated telehealth prescribing and mail dispensing of mifepristone nationwide, preserving existing access to the abortion pill while litigation continues [1]. The Court did not agree to hear the merits of the underlying case and returned the matter to the 5th Circuit for further proceedings [1]. Justices Samuel Alito and Clarence Thomas dissented publicly from the stay order [2].
The underlying case consolidates challenges brought by Danco Laboratories and GenBioPro against the State of Louisiana, with the Food and Drug Administration's risk-evaluation framework for mifepristone at the center of the dispute [1]. The 5th Circuit issued its ruling on May 1, holding in a manner that would have required in-person dispensing of the drug across the country [1]. That decision triggered emergency applications to the Supreme Court, which imposed a temporary freeze before converting it into the indefinite stay announced this week [2].
The stay restores the legal status quo for pharmacies, mail-order providers, and telehealth platforms that have relied on the FDA's current dispensing rules [2]. Justice Thomas, in a separate dissent, argued that mailing mifepristone violates the Comstock Act, a 19th-century federal statute prohibiting the mailing of obscene materials and items used for abortion [1]. Thomas's invocation of Comstock introduces a statutory argument that operates independently of the FDA regulatory question and could constrain any future congressional or executive effort to expand access by rule alone [1]. Alito's dissent signals that at least two justices view the stay as an improper intervention in ongoing lower-court proceedings [2].
The practical effect is temporary certainty for healthcare providers operating under telehealth and mail-dispensing protocols, but the legal posture remains unstable [2]. The 5th Circuit must now revisit the case on remand, and any ruling it issues will likely return to the Supreme Court on an expedited basis [1]. Given the written dissents, the composition of the Court, and the unresolved Comstock question, a second emergency posture before the justices is a near-certain prospect [1]. Providers and state regulators should treat the current stay as a litigation pause, not a resolution.